TPG Biotech

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Progyny, Inc. is a benefits management company based in New York that focuses on providing fertility and family-building benefits for employers in the United States. The company offers a comprehensive fertility benefits solution that includes a differentiated plan design, personalized support through dedicated Patient Care Advocates, and access to a selective network of high-quality fertility specialists. Progyny also features Progyny Rx, an integrated pharmacy benefit that supplies necessary medications for treatment. Additionally, the company covers surrogacy and adoption expenses for its clients and their employees. Established in 2008 and rebranded from Auxogyn, Inc. in 2015, Progyny aims to create inclusive solutions that enhance patient care while reducing healthcare costs for employers.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Adynxx is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative pain management therapies. Established in 2007, the company is working on a new class of therapeutics known as transcription factor decoys to address unmet medical needs in pain and inflammation treatment. Its pipeline features AYX1, a drug candidate aimed at preventing acute post-operative pain and its progression to chronic pain, and brivoligide, currently in Phase 2 trials for postoperative pain management. Additionally, Adynxx is developing AYX2, a pre-clinical candidate designed to treat chronic pain syndromes, including inflammatory and neuropathic pain.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Progyny, Inc. is a benefits management company based in New York that focuses on providing fertility and family-building benefits for employers in the United States. The company offers a comprehensive fertility benefits solution that includes a differentiated plan design, personalized support through dedicated Patient Care Advocates, and access to a selective network of high-quality fertility specialists. Progyny also features Progyny Rx, an integrated pharmacy benefit that supplies necessary medications for treatment. Additionally, the company covers surrogacy and adoption expenses for its clients and their employees. Established in 2008 and rebranded from Auxogyn, Inc. in 2015, Progyny aims to create inclusive solutions that enhance patient care while reducing healthcare costs for employers.

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at addressing pain management while mitigating the risks of prescription drug abuse. The company utilizes its proprietary DETERx platform technology, which ensures that its formulations maintain extended-release and safety profiles even when subjected to common methods of misuse such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone, and Nucynta products, which consist of both extended-release and immediate-release formulations of tapentadol. These offerings are designed to manage chronic pain and provide effective treatment solutions while incorporating tamper-resistant features to combat non-medical use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical was incorporated in 2002 and has focused on building a portfolio of innovative products that align with evolving patient needs and regulatory standards.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

8990 Holdings (HOUSE), formerly IP Converge Data Center, Inc., was incorporated as an information technology and telecommunications services provider on July 08, 2005. On October 1, 2013, the Securities and Exchange Commission approved the change in its corporate name to the present one and the change in its primary purpose to that of a holding company. In May 2012, Iholdings, Inc. (Iholdings), Januarius Resources Realty Corporation (Januarius) and Kwantlen Development, Inc. (Kwantlen) gained control of the Company through the acquisition of 61.4% of the outstanding capital stock of HOUSE. In May 2013, in line with the objective to consolidate certain real estate companies owned or controlled by Iholdings, Januarius and Kwantlen, the Company acquired all of the outstanding shares in 8990 Housing Development Corporation, 8990 Luzon Housing Development Corporation, Fog Horn, Inc., 8990 Leisure and Resorts Corporation, 8990 Davao Housing Development Corporation and 8990 Mindanao Housing Development Corporation.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

GoHealth Urgent Care focuses on delivering a patient-centered experience through its network of urgent care centers located in New York, Oregon, Washington, California, and Connecticut, with plans for expansion into additional markets. The company aims to provide seamless integration with leading health systems, enhancing access to emergency care. By collaborating with a broad network of physicians and clinicians, GoHealth offers urgent health services that prioritize affordability and convenience. The welcoming culture of care at their facilities supports an effortless patient journey, ensuring that individuals receive the urgent medical attention they need in a timely manner.

PatientSafe Solutions, located in San Diego, California, specializes in innovative mobile solutions for point-of-care healthcare delivery. The company's flagship product, the PatientTouch System, enhances the productivity and safety of care teams by streamlining workflows on a single handheld device. This wireless clinical mobility solution integrates various functionalities, including positive patient identification, care interventions, and real-time communication, which are essential for improving patient safety and clinical outcomes. The PatientTouch System is designed with hospital-grade durability and features a high-performance barcode scanner, a full-shift battery, and an intuitive interface, making it suitable for frontline clinicians. By consolidating communication and workflows, PatientSafe Solutions enables hospitals to minimize harm, reduce waste, and enhance overall productivity in care delivery. The company's contributions to healthcare technology have garnered recognition, including being listed among the top venture-backed healthcare companies.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

ChemEOR is an innovative company focused on providing chemicals used in well stimulation and enhanced oil recovery.

Alphabet Energy, Inc. specializes in waste heat recovery technology that transforms waste heat into electricity. The company offers a range of products, including power-generating combustors, thermoelectric devices, and both solid-state and liquid-cooled electrical generators, all designed to capture exhaust heat and convert it into usable electrical power. Their innovative products, developed from sustainable materials, can generate power from microwatts to megawatts, catering to diverse industries such as automotive, oil and gas, mining, and manufacturing. Alphabet Energy also provides the PowerModule-β Developer Kit, which allows users to test thermoelectric converters in various applications. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company is committed to improving fuel efficiency and reducing energy waste for clients both in the United States and internationally.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Tandem Diabetes Care, Inc. is a medical device company that specializes in designing, developing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Based in San Diego, California, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The t:slim X2 is available with various advanced technologies, such as Basal-IQ and Control-IQ, and features like G5 integration. In addition to its insulin pumps, Tandem offers the t:connect web-based data management application and the Sugarmate mobile app to assist users in managing their diabetes. The company has also entered into a development and commercialization agreement with Dexcom, Inc. Tandem Diabetes Care has expanded its product line to include the smaller Mobi pump and is working on a tubeless insulin delivery system. The majority of its revenue comes from the U.S., with a smaller portion from other developed markets.

Genomatica, Inc. is a biotechnology company based in San Diego, California, that specializes in developing manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. Utilizing a proprietary platform, the company creates fermentation-based processes and engineers microorganisms that facilitate the conversion of these feedstocks into valuable chemicals. Genomatica has commercialized processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is utilized in cosmetics and personal care products. The company is also advancing the development of bio-nylon and has a pipeline targeting the production of 20 different chemicals, including butadiene. Recognized for its innovative technology, Genomatica has received several awards, including the Kirkpatrick Award for notable chemical engineering advancements and the ICIS Innovation Award for its Brontide butylene glycol.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Alphabet Energy, Inc. specializes in waste heat recovery technology that transforms waste heat into electricity. The company offers a range of products, including power-generating combustors, thermoelectric devices, and both solid-state and liquid-cooled electrical generators, all designed to capture exhaust heat and convert it into usable electrical power. Their innovative products, developed from sustainable materials, can generate power from microwatts to megawatts, catering to diverse industries such as automotive, oil and gas, mining, and manufacturing. Alphabet Energy also provides the PowerModule-β Developer Kit, which allows users to test thermoelectric converters in various applications. Founded in 2009 and headquartered in Hayward, California, with an additional office in Houston, Texas, the company is committed to improving fuel efficiency and reducing energy waste for clients both in the United States and internationally.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

Elevance Renewable Sciences, Inc. specializes in producing and distributing specialty chemicals derived from plant oils through a process known as natural oil metathesis. Founded in 2007 and headquartered in Woodridge, Illinois, the company offers a diverse range of products including cleaning ingredients, coating materials, personal care components, surfactants, and polymer building blocks. These products find applications across various industries, such as agriculture, pharmaceuticals, and engineered polymers, contributing to sectors like detergents, coatings, and personal care items. In addition to its product offerings, Elevance provides manufacturing consulting, engineering, and technical consulting services related to intermediates and bio-based feedstocks, positioning itself to meet the evolving demands of a market valued at over $100 billion annually.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing therapeutics for ear disorders. The company markets OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for Ménière’s disease; OTO-313, a formulation for tinnitus in Phase I/II trials; and OTO-413, aimed at repairing cochlear synaptopathy and addressing speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, designed to prevent cisplatin-induced hearing loss, and OTO-6XX, which focuses on hair cell regeneration for severe hearing loss. Otonomy employs a proprietary formulation platform that enables sustained drug delivery from a single administration, enhancing treatment options for various ear-related conditions. The company also has strategic collaborations for gene therapy aimed at congenital hearing loss. Founded in 2008, Otonomy continues to lead advancements in otology through innovation and research.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.

Genomatica, Inc. is a biotechnology company based in San Diego, California, that specializes in developing manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. Utilizing a proprietary platform, the company creates fermentation-based processes and engineers microorganisms that facilitate the conversion of these feedstocks into valuable chemicals. Genomatica has commercialized processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is utilized in cosmetics and personal care products. The company is also advancing the development of bio-nylon and has a pipeline targeting the production of 20 different chemicals, including butadiene. Recognized for its innovative technology, Genomatica has received several awards, including the Kirkpatrick Award for notable chemical engineering advancements and the ICIS Innovation Award for its Brontide butylene glycol.

Tandem Diabetes Care, Inc. is a medical device company that specializes in designing, developing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Based in San Diego, California, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The t:slim X2 is available with various advanced technologies, such as Basal-IQ and Control-IQ, and features like G5 integration. In addition to its insulin pumps, Tandem offers the t:connect web-based data management application and the Sugarmate mobile app to assist users in managing their diabetes. The company has also entered into a development and commercialization agreement with Dexcom, Inc. Tandem Diabetes Care has expanded its product line to include the smaller Mobi pump and is working on a tubeless insulin delivery system. The majority of its revenue comes from the U.S., with a smaller portion from other developed markets.

Draths Corporation is a forward-thinking chemical company dedicated to the production of biobased materials for a variety of industries, including chemicals, pharmaceuticals, and food. The company specializes in manufacturing primary chemical ingredients using proprietary technologies that combine metabolic engineering, synthetic biology, and chemical synthesis. Its product offerings include a range of chemicals such as shikimic acid, aminoshikimic acid, quinic acid, butanetriol, phloroglucinol, caprolactam, vanillin, myo-inositol, dehydroshikimic acid, gallic acid, pyrogallol, and tetrahydroxybenzene. Draths' innovative platform technology allows for the creation of materials like nylons, plastics, paints, and resins from renewable feedstocks, significantly reducing carbon footprints while maintaining cost-effectiveness in comparison to traditional petroleum-based processes.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.

ProteoGenix is a company focused on the development and commercialization of diagnostic testing products aimed at the maternal-fetal health sector. Founded in 2002 and headquartered in Costa Mesa, California, with additional offices in Beaverton, Oregon, and Orange County, California, ProteoGenix specializes in non-invasive diagnostic tests. These tests are designed to detect various conditions including intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and Down syndrome. The company's efforts are directed towards enhancing maternal-fetal health outcomes through innovative diagnostic solutions.

Tandem Diabetes Care, Inc. is a medical device company that specializes in designing, developing, and marketing insulin delivery systems for individuals with insulin-dependent diabetes. Based in San Diego, California, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The t:slim X2 is available with various advanced technologies, such as Basal-IQ and Control-IQ, and features like G5 integration. In addition to its insulin pumps, Tandem offers the t:connect web-based data management application and the Sugarmate mobile app to assist users in managing their diabetes. The company has also entered into a development and commercialization agreement with Dexcom, Inc. Tandem Diabetes Care has expanded its product line to include the smaller Mobi pump and is working on a tubeless insulin delivery system. The majority of its revenue comes from the U.S., with a smaller portion from other developed markets.

moksha8 Pharmaceuticals, Inc. is a pharmaceutical company that operates in Brazil and Mexico, focusing on the licensing, marketing, and distribution of therapeutics. The company specializes in treatments for various medical fields, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory conditions. Established in 2006 and based in Berwyn, Pennsylvania, moksha8 has formed strategic alliances with several prominent organizations, including Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson. These partnerships enhance its ability to deliver innovative healthcare solutions in the Latin American market.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost, also aimed at reducing intraocular pressure in open-angle glaucoma patients. Additionally, Aerie is developing AVX-012, a clinical-stage candidate for dry eye, alongside AR-1105 and AR-13503, which are sustained-release implants targeting retinal diseases. Founded in 2005, Aerie Pharmaceuticals is headquartered in Durham, North Carolina, and has a collaborative research agreement with DSM, reflecting its commitment to advancing eye care solutions.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. Founded in 2003, the company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood test designed to assist healthcare providers in determining whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By leveraging genomic technologies, CardioDx aims to deliver critical information that enhances treatment decisions and improves patient outcomes while also addressing the overall cost of care in the United States.